These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 12387700)
41. [The role of endocannabinoid system in physiological and pathological processes in the eye]. Nadolska K; Goś R Klin Oczna; 2008; 110(10-12):392-6. PubMed ID: 19195174 [TBL] [Abstract][Full Text] [Related]
42. Plant, synthetic, and endogenous cannabinoids in medicine. Di Marzo V; Petrocellis LD Annu Rev Med; 2006; 57():553-74. PubMed ID: 16409166 [TBL] [Abstract][Full Text] [Related]
43. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. Kreutz S; Koch M; Ghadban C; Korf HW; Dehghani F Exp Neurol; 2007 Jan; 203(1):246-57. PubMed ID: 17010339 [TBL] [Abstract][Full Text] [Related]
44. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Mechoulam R; Hanu L Pain Res Manag; 2001; 6(2):67-73. PubMed ID: 11854768 [TBL] [Abstract][Full Text] [Related]
45. Role of cannabinoids in multiple sclerosis. Zajicek JP; Apostu VI CNS Drugs; 2011 Mar; 25(3):187-201. PubMed ID: 21323391 [TBL] [Abstract][Full Text] [Related]
46. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Di Carlo G; Izzo AA Expert Opin Investig Drugs; 2003 Jan; 12(1):39-49. PubMed ID: 12517253 [TBL] [Abstract][Full Text] [Related]
47. Cannabinoids and Neurogenesis: The Promised Solution for Neurodegeneration? Valeri A; Mazzon E Molecules; 2021 Oct; 26(20):. PubMed ID: 34684894 [TBL] [Abstract][Full Text] [Related]
48. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor. García C; Gómez-Cañas M; Burgaz S; Palomares B; Gómez-Gálvez Y; Palomo-Garo C; Campo S; Ferrer-Hernández J; Pavicic C; Navarrete C; Luz Bellido M; García-Arencibia M; Ruth Pazos M; Muñoz E; Fernández-Ruiz J J Neuroinflammation; 2018 Jan; 15(1):19. PubMed ID: 29338785 [TBL] [Abstract][Full Text] [Related]
53. Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases. Śledziński P; Nowak-Terpiłowska A; Zeyland J Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383838 [TBL] [Abstract][Full Text] [Related]
54. Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. Pryce G; Riddall DR; Selwood DL; Giovannoni G; Baker D J Neuroimmune Pharmacol; 2015 Jun; 10(2):281-92. PubMed ID: 25537576 [TBL] [Abstract][Full Text] [Related]
55. Established and potential therapeutic applications of cannabinoids in oncology. Walsh D; Nelson KA; Mahmoud FA Support Care Cancer; 2003 Mar; 11(3):137-43. PubMed ID: 12618922 [TBL] [Abstract][Full Text] [Related]
57. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Nucci C; Bari M; Spanò A; Corasaniti M; Bagetta G; Maccarrone M; Morrone LA Prog Brain Res; 2008; 173():451-64. PubMed ID: 18929127 [TBL] [Abstract][Full Text] [Related]
58. Cannabinoids: between neuroprotection and neurotoxicity. Sarne Y; Mechoulam R Curr Drug Targets CNS Neurol Disord; 2005 Dec; 4(6):677-84. PubMed ID: 16375685 [TBL] [Abstract][Full Text] [Related]
59. A Brief Background on Cannabis: From Plant to Medical Indications. Klumpers LE; Thacker DL J AOAC Int; 2019 Mar; 102(2):412-420. PubMed ID: 30139415 [TBL] [Abstract][Full Text] [Related]